Intelligencia AI provides data-driven insights to help life science companies de-risk drug development.
2021
Year invested
Fund II
MTIP Fund
Greece, USA
Location
Active Investment
Investment status
Predictive Analytics
Segment
Based on curated data, Intelligencia uses Machine Learning algorithms to assess, quantify, and reduce the risk of clinical development. With a focus on increasing R&D productivity, the company offers a suite of decision-making support solutions that enable its customers to minimize the risk of drug development, as well as streamline productivity and lower cost across key aspects of pre-clinical and clinical development, Portfolio Strategy, and Business Development. They have an attractive business model with more than 90% recurring revenues.
As a long-term investor with a track record of creating successful and sustainable businesses, our goal is to deliver attractive strategic and financial returns to our investors.
.svg)
.svg)
